Learning Objectives

Keynote 1 – Understanding rapid acting antidepressants

Dr. John Krystal



Keynote 2 – Computational models for depression and antidepressant action

Dr. Tiago Maia



Symposia 1 – Diagnosis and impact of TRD

Prof. Daniel Souery
Definitions of TRD


Dr. Koen Demyttenaere
Impact of TRD


Dr. Georgios Aislaitner
Health regulatory perspective – EMA





Symposia 2 – Atypical antipsychotic augmentation in TRD: an update

Prof. Siegfried Kasper
Clinical background and present state of the art


Dr. Ross Baker
Adjunctive brexpiprazole in major depression


Dr. Sharon Mates
Novel antipsychotics for TRD


Prof. Torgny Svensson
Underlying mechanisms of action, preclinical evidence



Symposia 3 – The glutamatergic approach for treatment of depression

Prof. Maurizio Popoli
Restoration by ketamine of stress-induced maladaptive plasticity: implications for pathophysiology and treatment


Dr. Gerard Sanacora
Insight into rapid acting antidepressants


Prof. Kenji Hashimoto
R-Ketamine or S-Ketamine?


Dr. Carlos Zarate
Ketamine and beyond



Symposia 4 – Psychopharmacology and brain stimulation in TRD

Dr. Pierre Blier
Evidence for adding 2 antidepressants in TRD


Prof. Maurizio Fava
New Add-on strategies in TRD


Dr. Georgios Petrides
Electroconvulsive Treatment in TRD


Prof. Thomas Schlaepfer
Neurostimulation in TRD



Symposia 5 – Results of the European Group for the Study of Resistant Depression

Prof. Siegfried Kasper
The programme of GSRD


Dr. Stuart Montgomery
To switch or augment?


Dr. Alessandro Serretti
Genetic findings in GSRD and STAR*D


Dr. Alexander Kautzky
Machine-learning approach for big data sets



Symposia 6 – Molecular and brain circuit mechanisms in depression

Dr. Dan Rujescu
Molecular mechanisms of resilience and depression


Dr. Alan Frazer
Role of hippocampus-prefrontal cortex circuit for antidepressant response


Dr. Rupert Lanzenberger
Circuit mechanisms of reward, anhedonia and depression


Dr. John Mann
Postmortem Brain Evidence of Mood Disorders